Isolation of Leishmania amastigote protein fractions which induced lymphocyte stimulation and remission of psoriasis.
A first generation polyvalent vaccine (AS100(1)) was manufactured with protein from several cultured leishmania species, which proved to be effective in the treatment of psoriasis. To determine the effective factor, a single blind trial with four monovalent second generation vaccines (AS100(2)) was done in 26 subjects, which also resulted in remission of psoriasis. AS100(2) vaccines were further purified, resulting in seven chromatography fractions (AS200) per species. In vitro testing of the fractions on blood lymphocytes resulted in subjects being categorized as low or high responders before treatment. Both responder groups had no statistical difference in clinical outcome after AS100(1) treatment. Subsequently, a single-blind trial in 55 subjects treated with AS200 fractions from Leishmania brasiliensis also induced remission of Psoriasis. Two HIV +/- subjects with plaque psoriasis experienced remission after treatment with AS100(1). There are factors in leishmania species which induce remission of psoriasis by stimulating lymphocytes.
O'Daly
Jose Antonio
JA
Astralis LTD, 75 Passaic Ave., Fairfield, NJ 07004, USA. joseodaly@aol.com
Lezama
R
R
Gleason
J
J
D000328:Adult; D000368:Aged; D000818:Animals; D000953:Antigens, Protozoan / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology; D005260:Female; D006678:HIV / Q000276:immunology*; D015658:HIV Infections / Q000150:complications / Q000276:immunology / Q000628:therapy; D006801:Humans; D007891:Leishmania / Q000276:immunology* / Q000378:metabolism; D054332:Leishmaniasis Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000276:immunology / Q000628:therapy*; D012074:Remission Induction
D000953:Antigens, Protozoan; D054332:Leishmaniasis Vaccines